TY - JOUR
T1 - Is a picture-perfect thrombectomy necessary in acute ischemic stroke?
AU - Chen, Ching Jen
AU - Chalhoub, Reda
AU - Ding, Dale
AU - Kumar, Jeyan S.
AU - Ironside, Natasha
AU - Kellogg, Ryan T.
AU - Worrall, Bradford B.
AU - Southerland, Andrew M.
AU - Jabbour, Pascal
AU - Wolfe, Stacey Q.
AU - Arthur, Adam S.
AU - Goyal, Nitin
AU - Fragata, Isabel
AU - Maier, Ilko
AU - Matouk, Charles
AU - Grossberg, Jonathan A.
AU - Kan, Peter
AU - Schirmer, Clemens M.
AU - Crowley, R. Webster
AU - Ares, William J.
AU - Ogilvy, Christopher S.
AU - Rai, Ansaar T.
AU - Levitt, Michael R.
AU - Mokin, Maxim
AU - Guerrero, Waldo R.
AU - Mascitelli, Justin R.
AU - Yoo, Albert J.
AU - Williamson, Richard
AU - Grande, Andrew Walker
AU - Crosa, Roberto Javier
AU - Webb, Sharon
AU - Psychogios, Marios N.
AU - Starke, Robert M.
AU - Spiotta, Alejandro M.
AU - Park, Min S.
N1 - Funding Information:
Competing interests MRL: Grants from the NIH (R01NS105692, R01NS088072, U24NS100654, UL1TR002319, R25NS079200) and the American Heart Association (18CDA34110295). Unrestricted educational grants from Medtronic, Stryker and Philips Volcano. Consultant for Medtronic. Minor equity/ownership interest in Proprio, Cerebrotech, Synchron. Adviser to Metis Innovative. JAG: Grants from the Georgia Research Alliance. Consultant for Cognition Medical. AJY: Grants from Medtronic, Cerenovus, Penumbra, and Stryker. Consultant for Penumbra and Cerenovus. Equity interest in Insera Therapeutics. RWC: Proctor for Medtronic and Cerenovus. AMS: Research support from Penumbra, Stryker, Medtronic, and Siemens. Consultant for Penumbra, Stryker, Terumo, and Arsenal. MM: Consultant for Medtronic and Cerenovus. Stock ownership in Serenity Medical, Synchron, and Endostream. RMS: Grants from the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, the NIH (R01NS111119-01A1, UL1TR002736, KL2TR002737), the National Center for Advancing Translational Sciences, the National Institute on Minority Health and Health Disparities, and Medtronic. Consultant for Penumbra, Abbott, Medtronic, InNeuroCo and Cerenovus. Others: None.
Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Background The benefit of complete reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 3) over near-complete reperfusion (≥90%, mTICI 2c) remains unclear. The goal of this study is to compare clinical outcomes between mechanical thrombectomy (MT)-treated stroke patients with mTICI 2c versus 3. Methods This is a retrospective study from the Stroke Thrombectomy and Aneurysm Registry (STAR) comprising 33 centers. Adults with anterior circulation arterial vessel occlusion who underwent MT yielding mTICI 2c or mTICI 3 reperfusion were included. Patients were categorized based on reperfusion grade achieved. Primary outcome was modified Rankin Scale (mRS) 0-2 at 90 days. Secondary outcomes were mRS scores at discharge and 90 days, National Institutes of Health Stroke Scale score at discharge, procedure-related complications, and symptomatic intracerebral hemorrhage. Results The unmatched mTICI 2c and mTICI 3 cohorts comprised 519 and 1923 patients, respectively. There was no difference in primary (42.4% vs 45.1%; p=0.264) or secondary outcomes between the unmatched cohorts. Reperfusion status (mTICI 2c vs 3) was also not predictive of the primary outcome in non-imputed and imputed multivariable models. The matched cohorts each comprised 191 patients. Primary (39.8% vs 47.6%; p=0.122) and secondary outcomes were also similar between the matched cohorts, except the 90-day mRS which was lower in the matched mTICI 3 cohort (p=0.049). There were increased odds of the primary outcome with mTICI 3 in patients with baseline mRS ≥2 (36% vs 7.7%; p=0.011; p interaction =0.014) and a history of stroke (42.3% vs 15.4%; p=0.027; p interaction =0.041). Conclusions Complete and near-complete reperfusion after MT appear to confer comparable outcomes in patients with acute stroke.
AB - Background The benefit of complete reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 3) over near-complete reperfusion (≥90%, mTICI 2c) remains unclear. The goal of this study is to compare clinical outcomes between mechanical thrombectomy (MT)-treated stroke patients with mTICI 2c versus 3. Methods This is a retrospective study from the Stroke Thrombectomy and Aneurysm Registry (STAR) comprising 33 centers. Adults with anterior circulation arterial vessel occlusion who underwent MT yielding mTICI 2c or mTICI 3 reperfusion were included. Patients were categorized based on reperfusion grade achieved. Primary outcome was modified Rankin Scale (mRS) 0-2 at 90 days. Secondary outcomes were mRS scores at discharge and 90 days, National Institutes of Health Stroke Scale score at discharge, procedure-related complications, and symptomatic intracerebral hemorrhage. Results The unmatched mTICI 2c and mTICI 3 cohorts comprised 519 and 1923 patients, respectively. There was no difference in primary (42.4% vs 45.1%; p=0.264) or secondary outcomes between the unmatched cohorts. Reperfusion status (mTICI 2c vs 3) was also not predictive of the primary outcome in non-imputed and imputed multivariable models. The matched cohorts each comprised 191 patients. Primary (39.8% vs 47.6%; p=0.122) and secondary outcomes were also similar between the matched cohorts, except the 90-day mRS which was lower in the matched mTICI 3 cohort (p=0.049). There were increased odds of the primary outcome with mTICI 3 in patients with baseline mRS ≥2 (36% vs 7.7%; p=0.011; p interaction =0.014) and a history of stroke (42.3% vs 15.4%; p=0.027; p interaction =0.041). Conclusions Complete and near-complete reperfusion after MT appear to confer comparable outcomes in patients with acute stroke.
KW - Stroke
KW - Thrombectomy
UR - http://www.scopus.com/inward/record.url?scp=85100908950&partnerID=8YFLogxK
U2 - 10.1136/neurintsurg-2020-017193
DO - 10.1136/neurintsurg-2020-017193
M3 - Article
C2 - 33593800
AN - SCOPUS:85100908950
SN - 1759-8478
VL - 14
SP - 111
EP - 116
JO - Journal of NeuroInterventional Surgery
JF - Journal of NeuroInterventional Surgery
IS - 2
ER -